REDWOOD CITY, July 17 — On a quiet stretch of industrial park off the 101, a medical revolution that began with a single biopsy sample has quietly reshaped the treatment of breast cancer worldwide. Since its introduction in 2004, the Oncotype DX test has moved from a novel idea to a standard of care, its reach extending from academic hospitals in Boston to community clinics in rural Australia.
The test, manufactured by Genomic Health, is now part of the Exact Sciences Corporation portfolio after that company acquired Genomic Health in 2019 for $2.8 billion. By the end of 2023, more than 1.5 million patients across the globe had been tested. On the ground, the numbers tell a story of uneven progress. In major U.S. academic centers, adoption among eligible patients with early-stage breast cancer exceeds 80%. But in community settings, where most Americans receive their care, that rate drops to between 50% and 70%.
Barriers on the ground
Doctors and patient advocates describe a landscape of persistent obstacles. Cost remains a primary barrier. Lack of awareness among both physicians and patients holds back wider use. Limited access to genetic counseling, particularly in underserved regions, further narrows the pipeline of patients who could benefit.
Real-world evidence has confirmed the test’s impact. A 2020 analysis from the National Cancer Database found that Oncotype DX testing reduces chemotherapy use by 25% to 30% in clinical practice. That finding, drawn from the nation’s largest cancer registry, translates into thousands of women each year who avoid the toxicity of chemotherapy without compromising their outcomes.
The test’s influence now extends beyond the clinic and into the very guidelines that define standard care. The National Comprehensive Cancer Network has incorporated Oncotype DX into its quality metrics. The American Society of Clinical Oncology’s Choosing Wisely campaign, which urges doctors to avoid unnecessary treatments, also includes the test. Educational initiatives from both organizations have helped drive adoption, though the gap between academic and community settings persists.
International adoption, uneven
Across the Atlantic and the Pacific, the picture is mixed. Canada, Europe and Australia have broadly embraced the test. In those regions, reimbursement systems have largely accommodated the cost. But in other countries, reimbursement challenges remain a stubborn barrier. The test’s manufacturer, Exact Sciences, continues to market and distribute the product globally, but the patchwork of national health systems means that access varies widely.
The scene at community oncology practices in parts of the American South or rural Midwest looks different from the academic centers where the test was first validated. There, the rate of adoption hovers in that 50% to 70% range — a reminder that even a proven technology takes time to reach every patient.
By nightfall in Redwood City, the research and development teams at Exact Sciences are likely looking ahead. The company has not announced new indications for the test in recent months, but the platform’s potential extends beyond breast cancer. Observers watch for expansion into other tumor types, where the same genomic approach could spare patients from unnecessary treatment.
Consult your doctor for medical advice.
